Viewing Study NCT07222761


Ignite Creation Date: 2025-12-24 @ 12:47 PM
Ignite Modification Date: 2025-12-29 @ 6:26 PM
Study NCT ID: NCT07222761
Status: NOT_YET_RECRUITING
Last Update Posted: 2025-10-30
First Post: 2025-10-28
Is NOT Gene Therapy: True
Has Adverse Events: False

Brief Title: A Study to Compare Linvoseltamab Monotherapy and Linvoseltamab + Carfilzomib Combination Therapy With Standard-of-Care Combination Regimens in Adult Participants With Relapsed/Refractory Multiple Myeloma (RRMM)
Sponsor: Regeneron Pharmaceuticals
Organization:

Study Modules

Identification Module Status Module Sponsor Collaborators Module Oversight Module Description Module Conditions Module Design Module Arms Interventions Module Outcomes Module Eligibility Module Contacts Locations Module